EUCTR2012-002339-27-GB进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis - RA - BUILD
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 684
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •are at least 18 years of age
- •have a diagnosis of adult-onset RA as defined by the ACR/EULAR 2010 Criteria for the Classification of RA
- •have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
- •have a C-reactive protein (or hsCRP) measurement =1.2 times the upper limit of normal (ULN)
- •have had an insufficient response or are intolerant to cDMARDs and either:
- •- have had regular use of a cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry
- •- For patients not receiving a cDMARD at the time of entry, the investigator will document in the patient’s history that the patient had failed, was unable to tolerate, or had a contraindication to treatment with a cDMARD.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
- •have started treatment with NSAIDs or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
- •are currently receiving concomitant treatment with MTX,
- •hydroxychloroquine, and sulfasalazine or combination of any 3
- •have ever received any biologic DMARD
- •have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study
- •have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
- •have had 3 or more joints injected with intraarticular corticosteroids corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
- •have active fibromyalgia that, in the investigator’s opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
- •have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis,
- •spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic
- •arthritis, or active vasculitis or gout
- •o Patients with secondary Sjogren's syndrome are not excluded.
- •have a diagnosis of Felty’s syndrome
- •have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the patient
- •have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure
- •have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data
- •are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
- •have an eGFR based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <40 mL/min/1.73 m2
- •have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ?1.5 times the ULN
- •have, or have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenop
研究者
相似试验
进行中（未招募）
1 期
A clinical study (Phase III) to assess the Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), when compared against placebo in a randomised, double blind manner.CMV reactivation after allogeneic stem cell transplantation.MedDRA version: 20.0Level: LLTClassification code 10049107Term: CMV viraemiaSystem Organ Class: 100000004862EUCTR2013-000903-18-DEAstellas Pharma Global Development, Inc. (APGD)514
进行中（未招募）
1 期
A clinical study (Phase III) to assess the Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), when compared against placebo in a randomised, double blind manner.CMV reactivation after allogeneic stem cell transplantation.MedDRA version: 19.1Level: LLTClassification code 10049107Term: CMV viraemiaSystem Organ Class: 100000004862EUCTR2013-000903-18-SEAstellas Pharma Global Development, Inc. (APGD)500
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Oropharyngeal Cancer (OPC)MedDRA version: 21.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000789-13-DEISA Therapeutics B.V.194
进行中（未招募）
1 期
A clinical trial looking at the use and safety of tadalafil for the treatment of Duchenne Muscular Dystrophy in children.MedDRA version: 16.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2013-001194-25-ESilly S.A.306
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000097-15-GRAbbVie Deutschland GmbH & Co. KG230